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Summary Neurofibromatosis type 1 (NF1; OMIM 162200), a dominantly inherited multitumor
syndrome, results from mutations in the Neurofibromin 1 (NF1) gene. We present
the case of a Hungarian woman with the clinical phenotype of NF1 over her whole
body and the clinical features of unilateral overgrowth involving her entire left leg.
This unusual phenotype suggested either the atypical form of NF1 or the coexistence
of NF1 and overgrowth syndrome. Direct sequencing of the genomic DNA isolated
from peripheral blood revealed a novel frameshift mutation (c.5727insT,
p.V1909fsX1912) in the NF1 gene. Next-generation sequencing of 50 oncogenes
and tumour suppressor genes, performed on the genomic DNAs isolated from tissue
samples and peripheral blood, detected only wild-type sequences. Based on these
results, we concluded that the patient is affected by an unusual phenotype of NF1,
and that the observed unilateral overgrowth of the left leg might be a rare conse-
quence of the identified c.5727insT mutation.
Neurofibromatosis type 1 (NF1; OMIM 162200) is a
rare monogenic disease with autosomal dominant
inheritance, caused by mutations in the Neurofibromin
1 (NF1) gene.1 The clinical features of NF1 involve
pigmentary changes such as cafe-au-lait macules and
axillary freckling, development of cutaneous fibroma-
tous tumours, and development of hamartomas of the
iris known as Lisch nodules.1 Besides these symptoms,
central nervous system and skeletal abnormalities
(scoliosis, pseudoarthrosis of the tibia, macrocephaly
and short stature) can occur.2,3 Frequently reported
vascular symptoms include vascular dysplasia with
cerebral, gastrointestinal and/or renal involvement,
and renovascular hypertension.2,3
NF1 may be caused by many different loss-of-
function mutations of the NF1 gene.1 In about 5% of
patients with NF1, microdeletions of the NF1 gene
and/or the surrounding genomic region are responsi-
ble for the disease.4 In patients with NF1 micro-
deletion, somatic overgrowth has been frequently
observed.5 Mosaic overgrowth affecting a well-defined
region of the body have only been rarely reported in
NF1.
We report the case of a Hungarian woman present-
ing with the classic clinical features of NF1 and with
unusual unilateral overgrowth of her left leg. The
symptoms of NF1 were visible over her whole body,
while the overgrowth was present only in her left leg.
Our aim was to identify the underlying genetic abnor-
mality of this unusual case and determine whether the
patient is affected by two independent diseases or
whether the symptoms of the left leg are an unusual
manifestation of NF1.
Report
A 52-year-old Hungarian woman presented with an
unusual phenotype, exhibiting the clinical features of
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NF1. The typical skin symptoms of NF1 were present
in the patient, including neurofibromas and cafe-au-
lait macules on her body (Fig. 1a,b), and axillary
freckling. Ophthalmological examination determined
the presence of Lisch nodules. Imaging studies did not
find any indication of central nervous system malig-
nancies. Skeletal abnormalities such as scoliosis, tibial
pseudoarthrosis, short stature and macrocephaly, were
not present. Based on the clinical symptoms, the diag-
nosis of NF1 was established.
However, in addition to the aforementioned clinical
features, the patient was also noted to have hyper-
trophy of the left leg, resulting in significant differences
in the circumference and length of the legs (Fig. 1c,d).
This abnormality of the left leg was already present at
birth. Imaging studies verified unilateral osteohyper-
trophy affecting the left leg. The patient was not
aware of any relevant chronic diseases or other family
members with NF1 or with overgrowth syndromes
(Fig. 1e).
Following ethics approved by the internal review
board of the University of Szeged (Szeged, Hungary),
genetic studies were carried out, conducted accord-
ing to the principles of the Declaration of Helsinki.
Written informed consent was obtained from all par-
ticipants. Tissue biopsy of the left leg and blood
sample were taken from the patient, and genomic
DNA was isolated (BioRobot EZ1 DSP Workstation;
QIAGEN, Hilden, Germany). Her family members
were unwilling to provide material for genetic inves-
tigation.
To confirm NF1, the coding regions and flanking
introns of the NF1 gene were amplified and
sequenced. Direct sequencing of genomic DNA isolated
from the peripheral blood sample revealed a novel
frameshift mutation (c.5727insT, p.V1909fsX1912) in
exon 39 of the NF1 gene (Fig. 2). The patient carried
the mutation in heterozygous form (Fig. 2a), while
unrelated controls (n=50) carried the wild-type
sequence (Fig. 2b).
To verify overgrowth syndrome, the coding regions
and flanking introns of the PIK3CA gene were ampli-
fied and sequenced. As traditional sequencing of geno-
mic DNA isolated from the peripheral blood and from
the tissue sample of the left leg did not identify any
putative causative variant of the PIK3CA gene, muta-
tional hotspots were screened using an in-house PCR-
based restriction fragment assay.6 As these also did
not identify any overgrowth-causing mutation, next-
generation sequencing of approximately 2800 muta-
tions from 50 oncogenes and tumour suppressor genes
recorded in the Catalogue of Somatic Mutations in
Cancer (COSMIC) was performed (Ion AmpliSeq™v
Cancer Hotspot Panel v2; Thermo Fisher Scientific,
Waltham, MA, USA), but also did not identify any
putative causative variant that could be responsible
for the overgrowth of the left leg.
This patient presented with the clinical features of
both NF1 and left leg overgrowth. Such an atypical
clinical form of NF1 has not been reported previously.
However, the phenomenon of ‘vascular neurofibro-
matosis phenotype’ and the relatively frequent
(a)
(b)
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Figure 1 An unusual phenotype of neurofibromatosis (NF)1 in a 52-year-old Hungarian woman. The patient presented with the clini-
cal phenotype of NF1 over her whole body, including (a) her chest and (b) back. (c,d) Unilateral osteohypertrophy affected the left leg.
(e) The rest of the patient’s family were clinically asymptomatic.
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association of NF1 with vascular dysplasia have been
frequently reported in the literature.7 NF1 can also be
accompanied by skeletal abnormalities, such as sphe-
noid wing dysplasia, macrocephaly, scoliosis, vertebral
disc dysplasia, pseudoarthrosis of tibia and short sta-
ture.8,9 Therefore, it was important to distinguish
whether the patient was affected by two independent
rare diseases or the symptoms of the left leg were the
results of the atypical vascular and skeletal manifesta-
tions of NF1.
Our results demonstrated a novel heterozygous
single-nucleotide insertion in the NF1 gene, leading to
a frameshift and the formation of a premature termi-
nation codon (c.5727insT, p.V1909fsX1912). Because
this mutation was present in the genomic DNA iso-
lated from the peripheral blood of the patient, we sug-
gest that this sequence change is a germline
mutation. Considering that there is no other clinically
affected member in the patient’s family and that NF1
exhibits autosomal dominant inheritance, we hypothe-
size that this is a de novo mutation of the NF1 gene.
The genotype–phenotype correlation is generally poor
in NF1, with the exception that patients with large
deletions in the NF1 gene tend to have severe pheno-
types.10 NF1 mutations usually result in loss of
tumour suppressor function by disrupting the NF1
protein’s ability to maintain the proto-oncogene RAS
in an inactive form.11 We suggest that this novel NF1
mutation is the causative mutation for the
development of NF1, and that it is highly possible that
the presence of the unilateral limb hypertrophy is also
the consequence of this mutation.
In conclusion, we report a patient with both the
clinical features of NF1 and overgrowth of the left leg.
To our knowledge, our study is the first to clearly elu-
cidate the genetic background of such a complex case,
and further confirms the causative role of the somatic
mutations of the NF1 gene in the development of
overgrowth.
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Learning points
• The case reported in this study was presented
with the clinical features of both NF1 and left leg
overgrowth.
Figure 2 (a,b) Direct sequencing of the NF1 gene. Direct sequencing revealed a novel single-nucleotide insertion resulting in a frame-
shift and the formation of premature termination codon (c.5727insT, p.V1909fsX1912). (a) The patient carried the mutation in
heterozygous form. (b) Unrelated, healthy controls carried only wild-type sequences.
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• The unusual clinical phenotype including the
left leg overgrowth is the atypical manifestation
of NF1.
• The patient carries a disease-causing germline
mutation of the NF1 gene.
• The patient does not carry any somatic muta-
tion of PIK3CA or other genes.
• Our study elucidates the genetic background of
the investigated case with unusal phenotype, and
confirms that the observed left leg overgrowth is
the consequence of NF1.
References
1 Huson SM. The neurofibromatosis: classification,
clinical features and genetic counselling. In:
Neurofibromatoses (Kaufmann D, ed). Basel: Karger,
2008; 1–20.
2 Mukonoweshuro W, Griffiths PD, Blaser S.
Neurofibromatosis type 1: the role of neuroradiology.
Neuropediatrics 1999; 30: 111–19.
3 Stevenson DA, Birch PH, Friedman JM et al. Descriptive
analysis of tibial pseudarthrosis in patients with
neurofibromatosis 1. Am J Med Genet 1999; 84: 413–19.
4 Pasmant E, Sabbagh A, Spurlock G et al. NF1
microdeletions in neurofibromatosis type 1: from
genotype to phenotype. Hum Mutat 2010; 31: 1506–18.
5 Spiegel M, Oexle K, Horn D et al. Childhood overgrowth
in patients with common NF1 microdeletions. Eur J Hum
Genet 2005; 13: 883–8.
6 Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, et al. Clinical
delineation and natural history of the PIK3CA-related
overgrowth spectrum. Am J Med Genet A 2014; 164A:
1713–33.
7 Reubi F. Neurofibromatose et lesions vasculaires. Schweiz
Med Wochenschr 1945; 75: 463–5.
8 Ferner RE, Huson SM, Thomas N et al. Guidelines for the
diagnosis and management of individuals with
neurofibromatosis 1. J Med Genet 2007; 44: 81–8.
9 Williams VC, Lucas J, Babcock MA et al.
Neurofibromatosis type 1 revisited. Pediatrics 2009; 123:
124–33.
10 Heim RA, Silverman LM, Farber RA et al. Screening for
truncated NF1 proteins. Nat Genet 1994; 8: 218–19.
11 Yohay KH. The genetic and molecular pathogenesis of
NF1 and NF2. Semin Pediatr Neurol 2006; 13: 21–6.
ª 2017 British Association of Dermatologists766 Clinical and Experimental Dermatology (2017) 42, pp763–766
Atypical neurofibromatosis mimicking overgrowth syndrome  K. Tripolszki et al.
